(Re)defining biopharmaceutical

Nature Biotechnology

Volumn 26, Issue 7, 2008, Pages 743-751

  Rader, Ronald A ^a  

^a Biotechnology Information Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APROTININ; APTAMER; ATORVASTATIN; EPICEL; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PNEUMOCOCCUS VACCINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VIVAGLOBULIN;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOMENCLATURE; NOTE; PNEUMONIA; PRIORITY JOURNAL; RNA INTERFERENCE; SEMANTICS; SKIN AUTOGRAFT;

BIOPHARMACEUTICS; DRUG INDUSTRY; INTERNATIONALITY; REFERENCE STANDARDS; TERMINOLOGY AS TOPIC;

EID: 46949105562     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0708-743     Document Type: Note

References (30)

1. Rader, R.A. Biopharmaceutical Products in the US and European Markets, 6th ed., 2 vols., (BioPlan Associates, Rockville, MD, 2007). 〈http://www.biopharma.com/〉
2. Rader, R.A. BioExecutive Intl., March, 60-65 (2005). 〈http://www.biopharma.com/BioExec_pt1.pdf〉
3. Rader, R.A. BioExecutive Intl., May, 42-49 (2005). 〈http://www.biopharma.com/BioExec_pt2.pdf〉
4. Walsh, G. & Jefferis, R. Nat. Biotechnol. 24, 1241-1252 (2006).
5. Akers, M.J. BioProcess Intl. 4, 36-43 (2006).
6. Webster, C. et al. BioPharm Intl. July, 1 (2003).
7. Copmann, T. et al. BioPharm Intl. March, 14-24 (2001).
8. Scott, C. BioProcess Intl. 3, 80 (2005). 〈http://www.bioprocessintl.com/default.asp?page=article_display&docid= 61200511&display=full/〉
9. Walsh, G. Eur. J. Pharm. Sci. 15, 135-138 (2002).
10. Eby, R.J. et al. The Story of Prevnar (Pharmaceutical Research and Manufacturers Association, Washington, DC, 2008). 〈http://www.innovation. org/index.cfm/StoriesofInnovation/InnovatorStories/The_Story_of_Prevnar/〉
11. http://www.bio.org/speeches/pubs/er/biotechguide.pdf
12. Ernst & Young. Beyond Borders: Ernst & Young Global Biotechnology Report 2007 (Ernst & Young, New York, 2007).
13. DeVol, R. et al. Biopharmaceutical Industry Contributions to State and US Economics (Milken Institute, Santa Monica, CA, USA, 2004). 〈http://www.milkeninstitute.org/pdf/biopharma_report.pdf〉
14. 〈http://www.burrillandco.com/burrill/pr_1171302475/〉
15. Ernst & Young. Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition (Ernst & Young, New York, 2000).
16. PhRMA. Introduction, 2005 Industry Profile (PhRMA, Washington, DC, 2006). 〈http://members.phrma.org/publications/publications//2005-03-17. 1144.pdf〉
17. PhRMA. Annual Report 2006-2007: Biopharmaceutical Inspiration, (PhRMA, Washington, DC, 2007). 〈http://www.phrma.org/files/ Annual_Report_2006_2007.pdf〉
18. Myshko, D. PharmaVOICE, October, 40-44 (2006).
19. Frantz, S. Nat. Rev. Drug Discov. 5, 977-979 (2006).
20. Simons, J. Fortune, 28 February 2006. 〈http://money.cnn.com/ 2006/02/27/news/companies/pluggedin_fortune/index.htm/〉
21. Anonymous. Seeking Alpha. 9 January 2007. 〈http:// seekingalpha.com/article/23696-the-biotech-industry-30-years-of-failure- starting-with-genentech/〉
22. Chase, M. The Wall Street Journal, p. B1 (June 5, 2007). 〈http://online.wsj.com/public/article/SB118100806142024548- PFa4u2AiKfDHi25uT1jv HmdJZKA_20070612.html?mod=blogs〉
23. Schoemaker, P. & Tomczyk, M.S. BioProcess Intl. 4, 64 (2006).
24. Rader, R.A. US BIOPHARMACOPEIA Registry of Biopharmaceutical Products (Biotechnology Information Institute, Rockville, MD, USA, 2007). 〈http://www.biopharmacopeia.com/〉
25. German Association of Research-Based Pharmaceutical Companies (VFA). Biological/Biotechnological Generics Cannot Exist (VFA, Berlin, Germany, July 25, 2006). 〈http://www.vfa.de/vfa-bio_en/vb_press/vb_positionen_en/ biosimilars.html〉
26. Miller, H.I. Trends Biotechnol. 5, 56-59 (2007).
27. Rader, R.A. BioProcess Intl. 5, 28-39 (March 2007). 〈http://www.biopharma.com/whatsabiogeneric_pt1.pdf〉
28. Rader, R.A. BioProcess Intl. 5, 20-27 (May 2007). 〈http://www.biopharma.com/whatsabiogeneric_pt2.pdf〉
29. Katz, K.A. Br. J. Dermatol. 154, 809-812 (2006).
30. 〈http://www.fda.gov/cber/faq.htm#3/〉